Search

Displaying results 3061 - 3070 of 4238 in total
  1. Drug

    Aniracetam

    go.drugbank.com/drugs/DB04599
    Investigational

    Compound with anti-depressive properties used as a mental performance enhancer.

  2. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

  3. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesol...

  4. Drug

    Mesoridazine

    go.drugbank.com/drugs/DB00933
    ApprovedWithdrawn

    A phenothiazine antipsychotic with effects similar to chlorpromazine.

  5. Drug

    OSU-6162

    go.drugbank.com/drugs/DB19178
    Investigational

    OSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).

  6. Drug

    Sulopenem

    go.drugbank.com/drugs/DB15284
    Investigational

    It is marketed as the prodrug [sulopenem etzadroxil] in combination with [probenecid].[L51768]

  7. Drug

    Pexelizumab

    go.drugbank.com/drugs/DB04949
    Investigational

    Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.

  8. Drug

    Dimenoxadol

    go.drugbank.com/drugs/DB01461
    ExperimentalIllicit

    In the United States it is classified as a Schedule I controlled drug. … Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative.

  9. Drug

    Dibromothymoquinone

    go.drugbank.com/drugs/DB04646
    Experimental

    At low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors, probably acting as a plastoquinone antagonist. … At higher concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of its inhibitory activity. [PubChem]

  10. Drug

    NSI-566

    go.drugbank.com/drugs/DB17954
    Investigational

    Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]